Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 6, 2011, Pages 1727-1736

  Boonen, Steven ^a   Adachi, J D ^b   Man, Z ^c   Cummings, S R ^d   Lippuner, K ^e   Torring O ^f   Gallagher, J C ^g   Farrerons, J ^h   Wang, A ⁱ   Franchimont, N ⁱ   San Martin, J ⁱ   Grauer, A ⁱ   McClung, M ^j  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b Charlton Medical Centre   (Canada)

^c Centro TIEMPO   (Argentina)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF BERN   (Switzerland)

^f STOCKHOLM SÖDER HOSPITAL   (Sweden)

^g CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

^h HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

ⁱ AMGEN INC   (United States)

^j OREGON OSTEOPOROSIS CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; DENOSUMAB; PLACEBO; VITAMIN D;

ADULT; AGED; ARTICLE; BONE DENSITY; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; FEMALE; FEMUR NECK; FRAGILITY FRACTURE; HIGH RISK PATIENT; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; RISK REDUCTION; TREATMENT DURATION; VERTEBRA FRACTURE; VITAMIN SUPPLEMENTATION;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; DOUBLE-BLIND METHOD; FEMALE; HIP FRACTURES; HUMANS; INCIDENCE; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; RANK LIGAND; RISK; SPINAL FRACTURES; TREATMENT OUTCOME;

EID: 79955117784     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-2784     Document Type: Article

References (46)

1. 2001 NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785-795
2. Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D 2000 Risk of mortality following clinical fractures. Osteoporos Int 11:556-561
3. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA 1999 Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353:878-882 (Pubitemid 29126875)
4. Cooper C, Atkinson EJ, Jacobsen SJ, O'Fallon WM, Melton 3rd LJ 1993 Population-based study of survival after osteoporotic fractures. Am J Epidemiol 137:1001-1005 (Pubitemid 23191067)
5. Ensrud KE, Thompson DE, Cauley JA, Nevitt MC, Kado DM, Hochberg MC, Santora 2nd AC, Black DM 2000 Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass. Fracture Intervention Trial Research Group. J Am Geriatr Soc 48:241-249 (Pubitemid 30164205)
6. Hasserius R, Karlsson MK, Nilsson BE, Redlund-Johnell I, Johnell O 2003 Prevalent vertebral deformities predict increased mortality and increased fracture rate in both men and women: a 10-year population-based study of 598 individuals from the Swedish cohort in the European Vertebral Osteoporosis Study. Osteoporos Int 14:61-68 (Pubitemid 36267902)
7. Leibson CL, Tosteson AN, Gabriel SE, Ransom JE, Melton LJ 2002 Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study. J Am Geriatr Soc 50:1644-1650 (Pubitemid 35192535)
8. Richmond J, Aharonoff GB, Zuckerman JD, Koval KJ 2003 Mortality risk after hip fracture. J Orthop Trauma 17:53-56
9. Shi N, Foley K, Lenhart G, Badamgarav E 2009 Direct healthcare costs of hip, vertebral, and non-hip, non-vertebral fractures. Bone 45:1084-1090
10. Burgess TL, Qian Y, Kaufman S, Ring BD, Van G, Capparelli C, Kelley M, Hsu H, Boyle WJ, Dunstan CR, Hu S, Lacey DL 1999 The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 145:527-538
11. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176 (Pubitemid 28180851)
12. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T 1998 Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597-3602
13. Bone HG, Bolognese MA, Yuen CK, Kendler DL, Wang H, Liu Y, San Martin J 2008 Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 93:2149-2157 (Pubitemid 351831529)
14. Lewiecki EM, Miller PD, McClung MR, Cohen SB, Bolognese MA, Liu Y, Wang A, Siddhanti S, Fitzpatrick LA 2007 Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low bone mineral density. J Bone Miner Res 22:1832-1841 (Pubitemid 351229299)
15. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ 2006 Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821-831 (Pubitemid 43290920)
16. Miller PD, Bolognese MA, Lewiecki EM, McClung MR, Ding B, Austin M, Liu Y, San Martin J, Amg Bone Loss Study Group 2008 Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 43:222-229
17. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C 2009 Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756-765
18. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535-1541 (Pubitemid 26411651)
19. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR 2007 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809-1822 (Pubitemid 46698462)
20. Harris ST, Watts NB, Li Z, Chines AA, Hanley DA, Brown JP 2004 Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis. Curr Med Res Opin 20:757-764 (Pubitemid 38685022)
21. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY 2004 The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459-468 (Pubitemid 38133766)
22. Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, Devogelaer JP, Curiel MD, Sawicki A, Goemaere S, Sorensen OH, Felsenberg D, Meunier PJ 2005 Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90:2816-2822 (Pubitemid 40686329)
23. Genant HK, Wu CY, van Kuijk C, Nevitt MC 1993 Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137-1148 (Pubitemid 23261108)
24. Gail M, Simon R 1985 Testing for qualitative interactions between treatment effects and patients subsets. Biometrics 41:361-372
25. Nevitt MC, Cummings SR, Stone KL, Palermo L, Black DM, Bauer DC, Genant HK, Hochberg MC, Ensrud KE, Hillier TA, Cauley JA 2005 Risk factors for a first-incident radiographic vertebral fracture in women > or = 65 years of age: the study of osteoporotic fractures. J Bone Miner Res 20:131-140 (Pubitemid 41716228)
26. Ross PD, Davis JW, Epstein RS, Wasnich RD 1991 Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 114:919-923
27. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077-2082 (Pubitemid 29014065)
28. Delmas PD, Genant HK, Crans GG, Stock JL, Wong M, Siris E, Adachi JD 2003 Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 33:522-532 (Pubitemid 37222378)
29. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Glüer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637-645 (Pubitemid 29384151)
30. Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB, Licata A, Benhamou L, Geusens P, Flowers K, Stracke H, Seeman E 2001 Risk of new vertebral fracture in the year following a fracture. JAMA 285:320-323 (Pubitemid 32095035)
31. Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P, Eisman JA, Fujiwara S, Kroger H, Mellstrom D, Meunier PJ, Melton 3rd LJ, O'Neill T, Pols H, Reeve J, Silman A, Tenenhouse A 2005 Predictive value of BMD for hip and other fractures. J Bone Miner Res 20:1185-1194 (Pubitemid 40863806)
32. Kanis JA, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B 2001 Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 12:989-995 (Pubitemid 34105967)
33. Donaldson LJ, Cook A, Thomson RG 1990 Incidence of fractures in a geographically defined population. J Epidemiol Community Health 44:241-245 (Pubitemid 20327430)
34. Hallberg I, Bachrach-Lindström M, Hammerby S, Toss G, Ek AC 2009 Health-related quality of life after vertebral or hip fracture: a seven-year follow-up study. BMC Musculoskelet Disord 10:135
35. Cummings SR, Kelsey JL, Nevitt MC, O'Dowd KJ 1985 Epidemiology of osteoporosis and osteoporotic fractures. Epidemiol Rev 7:178-208 (Pubitemid 15236006)
36. Greendale GA, DeAmicis TA, Bucur A, Bretsky P, Rowe JW, Reuben DB, Seeman T 2000 A prospective study of the effect of fracture on measured physical performance: results from the MacArthur Study - MAC. J Am Geriatr Soc 48:546-549 (Pubitemid 30263107)
37. Ismail AA, Cooper C, Felsenberg D, Varlow J, Kanis JA, Silman AJ, O'Neill TW 1999 Number and type of vertebral deformities: epidemiological characteristics and relation to back pain and height loss. European Vertebral Osteoporosis Study Group. Osteoporos Int 9:206-213 (Pubitemid 29182370)
38. Nevitt MC, Ettinger B, Black DM, Stone K, Jamal SA, Ensrud K, Segal M, Genant HK, Cummings SR 1998 The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med 128:793-800 (Pubitemid 28267711)
39. Haentjens P, Magaziner J, Colón-Emeric CS, Vanderschueren D, Milisen K, Velkeniers B, Boonen S 2010 Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med 152:380-390
40. Boonen S, Autier P, Barette M, Vanderschueren D, Lips P, Haentjens P 2004 Functional outcome and quality of life following hip fracture in elderly women: a prospective controlled study. Osteoporos Int 15:87-94 (Pubitemid 38252421)
41. Pols HA, Felsenberg D, Hanley DA, Stepán J, Muñoz-Torres M, Wilkin TJ, Qin-sheng G, Galich AM, Vandormael K, Yates AJ, Stych B 1999 Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 9:461-468 (Pubitemid 29231740)
42. Boonen S, Black DM, Colón-Emeric CS, Eastell R, Magaziner JS, Eriksen EF, Mesenbrink P, Haentjens P, Lyles KW 2010 Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. J Am Geriatr Soc 58:292-299
43. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut 3rd CH, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344-1352 (Pubitemid 29483192)
44. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY 2001 Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333-340 (Pubitemid 32107641)
45. Bolland MJ, Grey AB, Gamble GD, Reid IR 2010 Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab 95:1174-1181
46. Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S 2007 Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799-1809